📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Innova Captab Q3 FY26 Revenue Surges 42% to ₹450 Cr; Branded Generics Grow 79%
Innova Captab reported a strong Q3 FY26 with consolidated revenue growing 42.3% YoY to ₹450.3 crores, driven by a massive 79% surge in the branded generics segment. The CDMO business also showed steady growth of 29% YoY, contributing ₹298.7 crores to the top line. The newly commissioned Jammu facility is scaling up well, contributing ₹89 crores this quarter and nearing EBITDA break-even. Profitability remained robust with EBITDA rising 39.6% to ₹71.1 crores, maintaining a healthy margin of 15.8%.
Key Highlights
Consolidated Q3 revenue reached ₹450.3 crores, a 42.3% YoY increase from ₹316.4 crores.
Branded generics segment grew 79% YoY to ₹151.6 crores due to aggressive domestic and international expansion.
Jammu facility revenue rose to ₹89 crores from ₹60 crores in the previous quarter, nearing EBITDA break-even.
EBITDA increased by 39.6% YoY to ₹71.1 crores with margins steady at 15.8%.
Exports formed 35% of Q3 revenue mix, supported by new UK-MHRA and PIC/S certifications.
💼 Action for Investors
Investors should monitor the ramp-up of the Jammu facility, which has a potential revenue capacity of ₹1,400+ crores at optimum utilization. The strong growth in high-margin branded generics and expansion into regulated export markets provides a positive long-term outlook.
Innova Captab Declares ₹2 Interim Dividend; Sets January 30 as Record Date
Innova Captab Limited has declared an interim dividend of ₹2 per equity share, representing 20% of the face value of ₹10 each for FY 2025-26. The company has fixed January 30, 2026, as the record date to determine shareholder eligibility for the payout. In compliance with the Finance Act 2020, the dividend is taxable, and the company will deduct Tax at Source (TDS) based on the residential status and documentation provided by shareholders. Shareholders are required to submit relevant tax forms by 5:00 PM on the record date to ensure appropriate tax treatment.
Key Highlights
Interim dividend declared at ₹2 per equity share (20% of face value).
Record date for dividend eligibility is fixed as Friday, January 30, 2026.
TDS will be deducted based on documentation submitted via KFintech portal by Jan 30.
Dividend payments will be made exclusively through electronic modes like NEFT and RTGS.
The board meeting declaring this dividend was held on January 23, 2026.
💼 Action for Investors
Investors should ensure their bank account details are updated with their DP and submit Form 15G/15H by January 30 to minimize TDS impact.
Innova Captab Q3 FY26 Revenue Surges 42% YoY to ₹450 Cr; Branded Generics Up 79%
Innova Captab reported a strong Q3 FY26 with revenue growing 42.3% YoY to ₹450.3 crore, driven by a massive 79% jump in the Branded Generics segment. EBITDA increased by 39.6% to ₹71.1 crore, though margins slightly contracted to 15.8% from 16.1% due to higher employee and material costs. The company achieved significant regulatory milestones, including UK-MHRA and PIC/s GMP certifications, which are expected to boost international market access. The newly commercialized Jammu facility is ramping up, providing a long-term growth runway with significant tax incentives.
Key Highlights
Consolidated Revenue for Q3 FY26 grew 42.3% YoY to ₹450.3 crore, while 9M FY26 revenue reached ₹1,182.2 crore.
Branded Generics segment showed stellar performance with 79% YoY growth in Q3, reaching ₹151.6 crore.
EBITDA for the quarter rose 39.6% to ₹71.1 crore, maintaining a healthy margin of 15.8%.
Export contribution increased to 35% of total revenue in Q3 FY26, supported by new global GMP certifications.
The Jammu manufacturing facility, commercialized in Jan 2025, is eligible for GST-linked incentives totaling 300% of investment over 10 years.
💼 Action for Investors
Investors should monitor the capacity utilization ramp-up at the Jammu facility and the margin trajectory as the high-growth Branded Generics business scales. The stock remains a strong play on the Indian CDMO and generic export themes.
Innova Captab Q3 FY26 Revenue Jumps 42% YoY to ₹450.3 Cr; PAT Rises 23%
Innova Captab Limited delivered a robust performance in Q3 FY26, with revenue from operations surging 42.3% YoY to ₹450.3 crores. EBITDA followed suit with a 39.6% increase to ₹71.1 crores, although margins contracted slightly by 30 bps to 15.8%. The company reported a 23.2% growth in PAT for the quarter, reaching ₹42.1 crores. Additionally, the receipt of UK-MHRA and PIC/s certifications for its manufacturing units strengthens its international market prospects.
Key Highlights
Q3 FY26 Revenue from operations grew 42.3% YoY to ₹450.3 crores.
EBITDA for the quarter increased 39.6% YoY to ₹71.1 crores with a 15.8% margin.
Profit After Tax (PAT) for Q3 FY26 rose 23.2% YoY to ₹42.1 crores.
Received UK-MHRA GMP certification for Baddi unit and PIC/s compliance for Jammu facility.
9M FY26 Revenue reached ₹1182.2 crores, up 27.3% compared to 9M FY25.
💼 Action for Investors
The strong top-line growth and new global regulatory approvals suggest a positive outlook for the CDMO and export business. Investors should maintain a positive stance while monitoring if the company can improve its margins in upcoming quarters.
Innova Captab Q3 Profit Jumps 23% to ₹421.5 Mn; Declares ₹2 Interim Dividend
Innova Captab reported a strong 42.3% YoY increase in consolidated revenue to ₹4,502.93 million for Q3 FY26. Net profit for the quarter rose 23.2% to ₹421.49 million, while basic EPS improved to ₹7.37 from ₹5.97. The company also declared an interim dividend of ₹2 per share (20% of face value) with a record date of January 30, 2026. For the nine-month period ending December 2025, revenue reached ₹11,822.16 million with a total profit of ₹1,028.34 million.
Key Highlights
Consolidated revenue increased by 42.3% YoY to ₹4,502.93 million in Q3 FY26.
Consolidated net profit grew 23.2% YoY to ₹421.49 million for the quarter.
Declared an interim dividend of ₹2 per share (20% of face value) for FY 2025-26.
9M FY26 revenue reached ₹11,822.16 million, up from ₹9,289.35 million in 9M FY25.
Fixed January 30, 2026, as the record date for determining dividend eligibility.
💼 Action for Investors
The strong revenue growth and consistent dividend payout reflect positive operational momentum in the pharmaceutical segment. Investors may consider holding or accumulating on dips, given the double-digit profit growth and healthy cash distribution.
Innova Captab Q3 PAT Rises 23% YoY to ₹42.1 Cr; Declares ₹2 Interim Dividend
Innova Captab Limited reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 42.3% YoY to ₹4,502.93 million. Net profit for the quarter increased by 23.2% YoY to ₹421.49 million, showing significant recovery from the previous quarter's ₹296.70 million. The Board has declared an interim dividend of ₹2 per equity share (20% of face value). The record date for the dividend is fixed as January 30, 2026, with the company maintaining a healthy growth trajectory across its pharmaceutical segments.
Key Highlights
Consolidated Revenue from operations increased 42.3% YoY to ₹4,502.93 million.
Net Profit (PAT) grew 23.2% YoY to ₹421.49 million in Q3 FY26.
Interim Dividend of ₹2 per share declared with a Record Date of January 30, 2026.
Quarter-on-Quarter PAT saw a sharp rise of 42.1% from ₹296.70 million in Q2 FY26.
9M FY26 consolidated PAT reached ₹1,028.34 million compared to ₹986.85 million in 9M FY25.
💼 Action for Investors
Investors should view the strong sequential and year-on-year growth positively, especially the sharp recovery in margins compared to Q2. The stock remains attractive for those looking for growth in the CDMO and branded generics space, supported by a steady dividend payout.
Innova Captab Declares ₹2 Interim Dividend; Q3 Net Profit Rises 23% YoY to ₹421.5 Million
Innova Captab Limited reported a strong performance for Q3 FY26, with consolidated revenue from operations growing 42.3% YoY to ₹4,502.93 million. Net profit for the quarter increased by 23.2% YoY to ₹421.49 million, while EPS rose to ₹7.37 from ₹5.97 in the previous year's corresponding quarter. The Board has declared an interim dividend of ₹2 per equity share (20% of face value) with a record date of January 30, 2026. For the nine-month period ended December 2025, the company achieved a total income of ₹11,880.72 million.
Key Highlights
Consolidated Revenue from operations surged 42.3% YoY to ₹4,502.93 million in Q3 FY26.
Net Profit for the quarter stood at ₹421.49 million, up from ₹342.04 million in Q3 FY25.
Declared an interim dividend of ₹2 per equity share (20% of face value ₹10) for FY 2025-26.
Nine-month consolidated net profit reached ₹1,028.34 million compared to ₹986.85 million YoY.
Record date for the interim dividend is fixed as Friday, January 30, 2026.
💼 Action for Investors
Investors may view the strong revenue growth and dividend declaration as a sign of healthy cash flows and operational scaling. The stock remains a key watch in the pharmaceutical CDMO space given its consistent earnings growth.
Innova Captab Q3 FY26 Revenue Jumps 42% YoY to ₹4,503 Mn; Declares ₹2 Interim Dividend
Innova Captab Limited reported a robust performance for the quarter ended December 31, 2025, with consolidated revenue from operations rising 42.3% YoY to ₹4,502.93 million. Net profit for the quarter grew 23.2% YoY to ₹421.49 million, showing a strong recovery from the previous quarter's ₹296.70 million. The Board also declared an interim dividend of ₹2 per share (20% of face value) with a record date of January 30, 2026. This growth is supported by the consolidation of subsidiaries including Sharon Bio-Medicine and Univentis Medicare.
Key Highlights
Consolidated Revenue from Operations increased 42.3% YoY to ₹4,502.93 million.
Net Profit (PAT) grew 23.2% YoY to ₹421.49 million from ₹342.04 million in the previous year.
Declared an interim dividend of ₹2 per equity share with a record date of January 30, 2026.
Quarter-on-quarter (QoQ) profit showed a significant jump of 42% from ₹296.70 million in Q2 FY26.
Finance costs increased to ₹39.50 million in Q3 FY26 compared to just ₹1.66 million in Q3 FY25.
💼 Action for Investors
Investors should take note of the strong top-line growth and the company's ability to maintain dividend payouts. The significant QoQ recovery in margins is a positive sign, though rising finance costs warrant continued monitoring.
Innova Captab Board to Meet Jan 23 for Q3 Results and Interim Dividend Consideration
Innova Captab Limited has scheduled a board meeting on January 23, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board will also consider a proposal for declaring an interim dividend for the financial year 2025-26. If approved, the company has already fixed January 30, 2026, as the record date to determine shareholder eligibility for the payout. This dual announcement indicates potential cash returns to shareholders alongside the quarterly performance update.
Key Highlights
Board meeting scheduled for January 23, 2026, to review Q3 and 9M FY26 financial performance.
Proposal for an interim dividend for FY 2025-26 to be considered during the meeting.
Record date for the potential interim dividend is fixed as January 30, 2026.
Trading window for insiders remains closed from January 1, 2026, until 48 hours after the results are declared.
💼 Action for Investors
Investors should monitor the January 23 announcement for the dividend amount and earnings growth to assess the company's yield and operational health.